Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - amisulpride - oral tablet - 100mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - amisulpride - oral tablet - 100mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - amisulpride - oral tablet - 100mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

creo pharma ltd - amisulpride - oral tablet - 100mg

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100 mg/ml;   - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml   excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - amisulpride 100 mg - tablet - 100 mg - amisulpride 100 mg - amisulpride

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 400mg;   - film coated tablet - 400 mg - active: amisulpride 400mg   excipient: basic butylated methacrylate copolymer isopropyl alcohol lactose monohydrate macrogol 6000 magnesium stearate   methylcellulose microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 200mg;   - tablet - 200 mg - active: amisulpride 200mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 50mg;   - tablet - 50 mg - active: amisulpride 50mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

focus pharmaceuticals ltd - amisulpride - oral solution - 100 mg/ml - amisulpride